ADPT
What one share of Adaptive Biotechnologies holds
Biological Products, (No Diagnostic Substances)
Throughout our history, we have advanced the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities.
Adaptive Biotechnologies’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $1.98 |
|---|---|
| Profit | −$0.41 |
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$0.15 |
| Cash and investments | $1.07 |
| Debt | $0.00 |
| Book value | $0.90 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | $3.15 | −$3.50 | $0.20 | −$3.06 | — | −$18.42 |
| 2018 | $4.41 | −$3.67 | $0.50 | −$3.05 | — | −$20.10 |
| 2019 | $1.23 | −$1.01 | $0.16 | $2.81 | — | $4.56 |
| 2020 | $0.75 | −$1.11 | $0.14 | −$1.28 | — | $5.40 |
| 2021 | $1.10 | −$1.48 | $0.44 | −$1.81 | — | $4.27 |
| 2022 | $1.30 | −$1.40 | $0.11 | −$1.41 | — | $3.24 |
| 2023 | $1.18 | −$1.56 | $0.07 | −$1.16 | — | $2.13 |
| 2024 | $1.22 | −$1.08 | $0.02 | −$0.67 | — | $1.37 |
| 2025 | $1.83 | −$0.39 | $0.02 | −$0.32 | — | $1.42 |